Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | Pomoč | SLO | ENG

Naslov:Electrochemotherapy with bleomycin is effective in BRAF mutated melanoma cells and interacts with BRAF inhibitors
Avtorji:ID Jesenko, Tanja (Avtor)
ID Prosen, Lara (Avtor)
ID Čemažar, Maja (Avtor)
ID Potočnik, Tjaša (Avtor)
ID Serša, Gregor (Avtor)
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (642,09 KB)
MD5: 4268F07765109C2C577A3B058D51010F
 
Jezik:Angleški jezik
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Povzetek:The aim of the study was to explore the effectiveness of electrochemotherapy (ECT) during the treatment of melanoma patients with BRAF inhibitors. Its effectiveness was tested on BRAF mutated and non-mutated melanoma cells in vitro and in combination with BRAF inhibitors. Materials and methods. ECT with bleomycin was performed on two human melanoma cell lines, with (SK-MEL-28) or without (CHL-1) BRAF V600E mutation. Cell survival was determined using clonogenic assay to determine the effectiveness of ECT in melanoma cells of different mutation status. Furthermore, the effectiveness of ECT in concomitant treatment with BRAF inhibitor vemurafenib was also determined in BRAF mutated cells SK-MEL-28 with clonogenic assay. Results. The survival of BRAF V600E mutated melanoma cells was even lower than non-mutated cells, indicating that ECT is effective regardless of the mutational status of melanoma cells. Furthermore, the synergistic interaction between vemurafenib and ECT with bleomycin was demonstrated in the BRAF V600E mutated melanoma cells. Conclusions. The effectiveness of ECT in BRAF mutated melanoma cells as well as potentiation of its effectiveness during the treatment with vemurafenib in vitro implies on clinical applicability of ECT in melanoma patients with BRAF mutation and/or during the treatment with BRAF inhibitors.
Ključne besede:electrochemotherapy, BRAF inhibitors, vemurafenib, melanoma
Status publikacije:Objavljeno
Verzija publikacije:Objavljena publikacija
Datum objave:01.09.2016
Založnik:Association of Radiology and Oncology
Leto izida:2016
Št. strani:str. 274-279, III
Številčenje:Vol. 50, no. 3
Izvor:Ljubljana
PID:20.500.12556/DiRROS-18867 Novo okno
UDK:602.6/.7
ISSN pri članku:1318-2099
DOI:10.1515/raon-2016-0042 Novo okno
COBISS.SI-ID:2416507 Novo okno
Avtorske pravice:by Authors
Datum objave v DiRROS:30.04.2024
Število ogledov:119
Število prenosov:27
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
:
Kopiraj citat
  
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Radiology and oncology
Skrajšan naslov:Radiol. oncol.
Založnik:Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:1318-2099
COBISS.SI-ID:32649472 Novo okno

Sekundarni jezik

Jezik:Slovenski jezik
Ključne besede:elektrokemoterapija, zaviralci BRAF, vemurafenib, melanom


Nazaj